News
SLP
18.40
+0.11%
0.02
Weekly Report: what happened at SLP last week (0810-0814)?
Weekly Report · 4d ago
Simulations Plus Advances Toward Altaris Acquisition With HSR Clearance
TipRanks · 08/13 21:41
Simulations Plus Clears HSR Waiting Period For Altaris Acquisition, Closing Expected In H2 2026
Benzinga · 08/13 21:02
Press Release: Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris
Dow Jones · 08/13 21:00
Weekly Report: what happened at SLP last week (0803-0807)?
Weekly Report · 08/10 09:42
Weekly Report: what happened at SLP last week (0727-0731)?
Weekly Report · 08/03 09:41
Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP
Barchart · 07/30 11:05
Simulation Plus, Inc. (NASDAQ: SLP) Investors Should Contact Robbins LLP for Information About Investigation
Barchart · 07/27 19:06
Weekly Report: what happened at SLP last week (0720-0724)?
Weekly Report · 07/27 09:44
Simulations Plus Sets Shareholder Vote on Cash Merger with Altaris Affiliate
TipRanks · 07/22 21:47
Weekly Report: what happened at SLP last week (0713-0717)?
Weekly Report · 07/20 09:42
Simulations Plus: The Potential Little Spread Is Not Worth The Risk For New Money, Hold
Seeking Alpha · 07/19 10:14
Weekly Report: what happened at SLP last week (0706-0710)?
Weekly Report · 07/13 09:43
Dow Gains 50 Points; Simulations Plus Earnings Top Views
Benzinga · 07/10 16:38
Simulations Plus Reports Profitability Rebound Ahead of Altaris Acquisition Close
Barchart · 07/10 16:01
Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)
TipRanks · 07/10 12:01
Simulation Plus Q3 Returns To Profit, Revenues Rise
NASDAQ · 07/10 10:43
Simulations Plus Affirms FY2026 Adj EPS Guidance of $0.75-$0.85 vs $0.42 Est; Affirms FY2026 Sales Guidance of $79.000M-$82.000M vs $81.598M Est
Benzinga · 07/10 06:48
Delta Air Lines, Netflix and 3 Stocks to Watch Heading Into Friday
Benzinga · 07/10 06:39
Simulations Plus Reports Q3 Growth and Profit Turnaround
TipRanks · 07/09 20:33
More
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.